AxoGen, Inc. announced that the company is making certain changes to its commercial organization designed to leverage the strength of its growing portfolio of clinical data and support innovation of advanced nerve repair solutions. As a result of these changes, the sales organization will report directly to Karen Zaderej, Axogen's chairman, CEO, and president, and the company anticipates appointing a chief marketing officer in the coming months. Eric Sandberg, the Company's current chief commercial officer will be leaving the organization effective July 19, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.04 USD | +1.17% | +5.04% | -11.57% |
May. 16 | AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft | MT |
May. 02 | Transcript : AxoGen, Inc., Q1 2024 Earnings Call, May 02, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.57% | 264M | |
+12.15% | 227B | |
+14.90% | 197B | |
+18.22% | 141B | |
+29.15% | 110B | |
+0.65% | 64.15B | |
+16.92% | 53.72B | |
+6.33% | 51.75B | |
+10.93% | 45.2B | |
+5.87% | 37.37B |
- Stock Market
- Equities
- AXGN Stock
- News AxoGen, Inc.
- Eric Sandberg, Current Chief Commercial Officer Will Be Leaving AxoGen, Inc